Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H15NO2 |
Molecular Weight | 217.2637 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CCC(=O)NC1=O)C2=CC=CC=C2
InChI
InChIKey=JMBQKKAJIKAWKF-UHFFFAOYSA-N
InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)
DescriptionSources: https://www.drugs.com/mmx/glutethimide.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01437 | https://www.ncbi.nlm.nih.gov/pubmed/2549762 | https://www.ncbi.nlm.nih.gov/pubmed/14193389
Sources: https://www.drugs.com/mmx/glutethimide.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01437 | https://www.ncbi.nlm.nih.gov/pubmed/2549762 | https://www.ncbi.nlm.nih.gov/pubmed/14193389
Glutethimide is a GABA agonist that was introduced by Ciba in 1954 as a safe alternative to barbiturates to treat insomnia. Before long, however, it had become clear that glutethimide was just as likely to cause addiction and caused similarly severe withdrawal symptoms. Glutethimide was discontinued in the US by manufacturers in 1993. Current production levels in the United States point to it only being used in small-scale research.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2845220 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GLUTETHIMIDE Approved UseUnknown Launch Date1976 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5568259/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLUTETHIMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
5 μg/mL |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLUTETHIMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
6.5 μg/mL |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLUTETHIMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.51 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/902458/ |
500 mg 3 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
GLUTETHIMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.6 h |
GLUTETHIMIDE serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5568259/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLUTETHIMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g multiple, oral (max) Overdose Dose: 4 g Route: oral Route: multiple Dose: 4 g Sources: Page: p.561 |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: alcohol addiction Age Group: 42 Sex: F Population Size: 1 Sources: Page: p.561 |
Disc. AE: Cerebellar ataxia... AEs leading to discontinuation/dose reduction: Cerebellar ataxia (severe) Sources: Page: p.561 |
10 g single, oral (min) Overdose |
unknown |
Disc. AE: Coma... AEs leading to discontinuation/dose reduction: Coma (grade 4-5) Sources: |
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: Page: p.72, 74 |
healthy n = 1 Health Status: healthy Sex: F Population Size: 1 Sources: Page: p.72, 74 |
Disc. AE: Unconsciousness, Uremia... AEs leading to discontinuation/dose reduction: Unconsciousness (grade 4) Sources: Page: p.72, 74Uremia (severe) Multiorgan failure (severe) Multiple congenital abnormalities (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cerebellar ataxia | severe Disc. AE |
4 g multiple, oral (max) Overdose Dose: 4 g Route: oral Route: multiple Dose: 4 g Sources: Page: p.561 |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: alcohol addiction Age Group: 42 Sex: F Population Size: 1 Sources: Page: p.561 |
Coma | grade 4-5 Disc. AE |
10 g single, oral (min) Overdose |
unknown |
Unconsciousness | grade 4 Disc. AE |
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: Page: p.72, 74 |
healthy n = 1 Health Status: healthy Sex: F Population Size: 1 Sources: Page: p.72, 74 |
Multiorgan failure | severe Disc. AE |
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: Page: p.72, 74 |
healthy n = 1 Health Status: healthy Sex: F Population Size: 1 Sources: Page: p.72, 74 |
Multiple congenital abnormalities | severe Disc. AE |
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: Page: p.72, 74 |
healthy n = 1 Health Status: healthy Sex: F Population Size: 1 Sources: Page: p.72, 74 |
Uremia | severe Disc. AE |
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: Page: p.72, 74 |
healthy n = 1 Health Status: healthy Sex: F Population Size: 1 Sources: Page: p.72, 74 |
PubMed
Title | Date | PubMed |
---|---|---|
Neurological effects of glutethimide. | 1968 Dec |
|
Anti-convulsant effect of phthalazino-2,3b-phthalazine-5(14H),12(7h)-dione (L-5418). I. Behavioral effect. | 1978 Feb |
|
Catatonia associated with glutethimide withdrawal. | 1983 Jan |
|
Lack of correlation between plasma 4-hydroxyglutethimide and severity of coma in acute glutethimide poisoning. A case report and brief review of the literature. | 1987 Jul-Aug |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mmx/glutethimide.html
Usual adult dose: 500 mg at bedtime; dose may be repeated if necessary, but not less than four hours before patient arises
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10564780
Chick embryo liver cells (CELCs) and chicken hepatoma cell line (LMH) were used to evaluate 5-Aminolevulinic acid synthase (ALA synthase) activity. CELCs and LMH cells were treated with Glutethimide (50mkM) or Glutethimide (50mkM)+ 4,6-dioxoheptanoic acid (0-500mkM)) and maintained for 18 h, after which cells were harvested, sonicates prepared and used to measure ALA synthase activity. The combination of glutethimide and DHA synergistically increased ALA synthase activity in both CELCs and LMH cells
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
||
|
DEA NO. |
2550
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
||
|
WHO-VATC |
QN05CE01
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
||
|
WHO-ATC |
N05CE01
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D005984
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
201-012-0
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
1313
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
484
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
4903
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
3487
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
100000084210
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
3088
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL1102
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
95239
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
m5783
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
C8I4BVN78E
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
7192
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
GLUTETHIMIDE
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
C65807
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
SUB07945MIG
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
77-21-4
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
DB01437
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY | |||
|
DTXSID1023102
Created by
admin on Fri Dec 15 15:37:43 GMT 2023 , Edited by admin on Fri Dec 15 15:37:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)